http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-059917-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D301-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D303-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C237-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10
filingDate 2007-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a66a3bb7341011ffad54416f15eed25a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23a8ecdd42bb7886ef96624097a12c07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_696959e8cca8fe6057d0f8aafd3979fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dad2514f2e73c34cc0ef13f0b90dfbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f30fc1540b6e0446e4a1be21f01c0299
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8db02b6583842c1066973dc388053707
publicationDate 2008-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-059917-A1
titleOfInvention PROTEASE INHIBITORS OF HEPATITIS C DEUTERATED. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS.
abstract Processes for obtaining said compounds and pharmaceutical compositions containing them. Claim 1: An alpha-ketoamido compound enriched with deuterium of the formula (1), wherein: D denotes a deuterium atom; R1 as in formula (2) wherein the ring is an optionally substituted monocyclic azaheterocyclyl or optionally substituted multicyclic azaheterocyclyl or optionally substituted multicyclic azaheterocyclyl, wherein the unsaturation is in a distal ring relative to the ring bearing the R21 moiety and to which the R21 moiety is attached. residue -C (O) -N (R2) -CDR3-C (O) -C (O) -NR4R5; R21 is Q3-W3-Q2-W2-Q1; where each of W2 and W3 is, independently, a link, -CO-, -CS-, -C (O) N (Q4) -, -CO2-, -O-, -N (Q4) - C (O) -N (Q4) -, - N (Q4) -C (S) -N (Q4) -, -OC (O) NQ4-, -S-, -SO-, -SO2-, -N (Q4) -, -N (Q4) SO2-, -N (Q4) SO2N (Q4) - and hydrogen when any of W2 and W3 is the terminal group; each of Q1, Q2 and Q3 is, independently, a bond, an optionally substituted aliphatic, an optionally substituted heteroaliphatic, an optionally substituted cycloaliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl or an optionally heteroaralkyl replaced; or hydrogen when any of Q3, Q2 or Q1 is the terminal group, with the proviso that Q2 is not a bond when both W3 and W2 are present; and each of R2, R3 and R4, independently, is H or a C1-6 alkyl; and R5 is H, alkyl, cycloalkyl, aryl optionally substituted with 1-4 alkyl, alkylaryl, aryl, amino groups optionally substituted with 1 or 2 alkyl groups.
priorityDate 2006-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559591
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID167583

Total number of triples: 36.